Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: web + 0.12  Related to the article below (Last Update: 8/4/2008)

Web.com Reports Second Quarter 2008 Financial Results
istockAnalyst.com, OR -
"Despite challenging economic conditions, Web.com was able to hit the top of its quarterly revenue and earnings guidance. The operating leverage potential ...
Anadarko Announces Second-Quarter Results
WELT ONLINE, Germany -
A replay of the call will also be available on the Web site for approximately 30 days following the conference call. ANADARKO OPERATIONS REPORT For more ...APC - BOM:500312 - WAR:CFL

RTT News
TheStreet.com Reports Second-Quarter Financial Results
MarketWatch - Jul 31, 2008
It engages audiences on video and digital platforms through some of the Web's best known sites: TheStreet.com, RealMoney.com, Stockpickr.com, ...
Conexant Reports Financial Results for the Third Quarter of Fiscal ... Trading Markets (press release)
Virtual Radiologic Corp. Reports Second Quarter 2008 Revenue ... CNNMoney.com (press release)
LoopNet, Inc. Announces Second Quarter 2008 Financial Results Trading Markets (press release)
all 535 news articles »  CNXTD - VRAD - TSCM

Space Ref (press release)
NASA OIG Audit of International Space Station Contracts Government ...
Space Ref (press release) -
While the total dollar value negotiated was minor [$260330 of $213977647 (0.12 percent) or $2065311 projected to the entire population], the documentation ...

Earthtimes (press release)
Fisher Communications, Inc. Reports Second Quarter Financial ...
MarketWatch - Jul 31, 2008
A live audio webcast of the call will be accessible to the public on Fisher's Web site, www.fsci.com. A recording of the webcast will subsequently be ...
Caraustar Industries, Inc. Reports Second Quarter Results Earthtimes (press release)
Kaydon Corporation Reports Second Quarter Results Barron's Blogs
Chiquita Reports Strong Second Quarter 2008 Results PR Newswire (press release)
Trading Markets (press release) - MarketWatch
all 1,378 news articles »  FIRE - CQB - CSAR
June 2008 - Quarterly Activities Report
Sydney Morning Herald, Australia - Jul 30, 2008
... results including: KB-1 Magmatic Copper-Nickel Target - 2.57% Cu, 0.12% Ni - 1.88% Cu, 0.12% Ni KB-2 Gold-Silver / Base Metals Target - 31.2 g/t Au, ...ASX:WMT - LON:URA
Belo Reports Results for Second Quarter 2008
FOXBusiness - Jul 25, 2008
Advertising revenue associated with Belo's Web sites increased 7.3 percent to $7.5 million in the second quarter 2008, representing 4 percent of Belo's ...
Superior Uniform Group Reports Continued Improvement in Operating ... MarketWatch
all 179 news articles »  SGC - BLC - OTC:CMTX
Tasty Baking Company Reports Second Quarter 2008 Results
MarketWatch - Aug 1, 2008
Investors will have the opportunity to listen to the call over the Internet at Tasty Baking Company's web site, http://www.tastykake.com. ...TSTY
Mercer International Inc. Reports 2008 Second Quarter Results
Stockhouse, Canada - Jul 30, 2008
In the first half of 2007, we reported net income from continuing operations of euro 4.4 million, or euro 0.12 per basic and diluted share. ...MERC

Earthtimes (press release)
Highwoods Properties Reports Second Quarter 2008 Results
Trading Markets (press release), CA - Jul 29, 2008
A live listen-only Web cast can be accessed through the Company's web site at www.highwoods.com under the "Investor Relations" section. ...
Cogdell Spencer Inc. Reports Second Quarter 2008 Financial Results Earthtimes (press release)
all 211 news articles »  HIW - CSA
Source: Google News

Copper coordination geometry in azurin undergoes minimal change on reduction of copper (II) to …
WEB Shepard, BF Anderson, DA Lewandoski, GE Norris … - Journal of the American Chemical Society, 1990 - pubs.acs.org
... Distance of Cu from Plane through N6,(46), Sy(ll2), and N6,(1 17). 8, 0.12 0.16
0.14 0.16 0.09 0.12 ' Bond distances and angles within the trigonal plane. ...

Contact Sex Signals on Web and Cuticle of Tegenaria atrica (Araneae, Agelenidae) -
O Prouvost, M Trabalon, M Papke, S Schulz - Archives of Insect Biochemistry and Physiology, 1999 - doi.wiley.com
... Receptive females Unreceptive females Determination Web Cuticle Web Cuticle ... Docosanoic
0.35 (0.06) 0.41 (0.12) Hexacosanoic 0.64 (0.12) 0.83 (0.32) ...

A comparison of development effort estimation techniques for Web hypermedia applications -
E Mendes, I Watson, C Triggs, N Mosley, S Counsell - Software Metrics, 2002. Proceedings. Eighth IEEE Symposium …, 2002 - ieeexplore.ieee.org
... In the Web engineering literature, the adaptation used to date is the mean of the
closest analogies ... MMRE MdMRE Pred(25) Yes 0.12 0.10 88.24 1 Mean No 0.11 0.09

The ocean?s food web, a changing paradigm
LR Pomeroy - Bioscience, 1974 - JSTOR
... form the basis of the established paradigm of the food web, but nannoplankton ... 1971
Peru Current (Equador) 0.09 Malone 1971 E. tropical Pacific 0.12 Malone 1971 ...

[PDF] Removal policies in network caches for world-wide web documents -
S Williams, M Abrams, CR Strandridge, G Abdulla, E … - Computer Communication Review, 1996 - cs.kent.edu
... caching in networks with workloads like ours could dramat- ically reduce the load
on popular Web servers. ... CGI 0.13 0.08 0.15 0.12 0.12 0.03 0.22 0.00 0.95 0.05 ...
-

Regulation of Lake Primary Productivity by Food Web Structure -
SR Carpenter, JF Kitchell, JR Hodgson, PA Cochran, … - Ecology, 1987 - JSTOR
... moved offshore immediately after release. December 1987 LAKE PRODUCTIVITY AND FOOD
WEB STRUCTURE 1871 in ... n = 9) than in 1984 (mean = 0.96 g/m2, SE -- 0.12, n = 9 ...

Effect of Scale on Food Web Structure -
ND Martinez - Science, 1993 - sciencemag.org
... Also in line with the convention, an eighth food web property, connectance, is inferred ...
0.057, R2 = 0.07), 1 = 0.284S + 33 (SEsiope = 0.110, R2 = 0.12), and B ...

[PDF] Phylogenetic constraints and adaptation explain food-web structure -
MF Cattin, LF Bersier, C Banasek-Richter, R … - Nature, 2004 - unifr.ch
... by one order of magnitude?in the prediction of these standard food-web descriptors ...
Lo 0.25 [0.12] 0.40 ? 0.05 [0] 0.13 0.00 [0.24] 0.02 0.01 [0] 0.06 0.26 [0 ...
-

[PDF] An Adaptive Agent for Web Exploration Based on Concept Hierarchies -
S Parent, B Mobasher, S Lytinen - Proceedings of the 9th International Conference on Human …, 2001 - maya.cs.depaul.edu
... On the other hand, a user interested in searching the Web for specific medical ... music:
1.000 blue: 0.15 new: 0.14 artist: 0.13 jazz: 0.12 review: 0.12 band ...

Production of Dimethylsulfonium Propionate (DMSP) and Dimethylsulfide (DMS) by a Microbial Food Web -
SK Kim, F Rassoulzadegan, B Krajka, BC Nguyen, N … - Limnology and Oceanography, 1990 - JSTOR
... we calcu- lated it with a constant DMS loss through the membranes (0.12 nM hl). ... that
decomposition of DMSP into DMS in the microbial food web involves several ...

Source: Google Scholar
 
 

Preliminary Results From Sunesis Pharmaceuticals' Phase 1 Trial Of SNS-595 In Patients With Advanced Leukemias Show Promising Clinical Activity

Article Date: 11 Dec 2006 - 0:00am (PST)
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data on its lead compound, SNS-595, from an ongoing Phase 1 clinical trial and from preclinical studies at The American Society of Hematology (ASH) 48th Annual Meeting and Exposition in Orlando, FL. Interim results from the Phase 1 clinical trial demonstrate that SNS-595 is well tolerated and shows promising signs of clinical activity in patients with advanced acute leukemias. In a second presentation, preclinical data from in vivo mice xenograph studies showed that SNS-595 acts synergistically with cytarabine to reversibly ablate bone marrow. SNS-595 is a naphthyridine analog that selectively targets and kills proliferating cells during the DNA replication phase of the cell cycle.

"SNS-595's activity among patients with advanced relapsed or refractory acute leukemias is encouraging as there is no standard treatment regimen for such patients, who generally have a very poor prognosis," said Jeffrey E. Lancet, M.D., Professor, Department of Hematologic Malignancies of the H. Lee Moffitt Cancer Center & Research Institute and a principal investigator for the Phase 1 trial. "To date, we've seen significant blast reductions within bone marrow and peripheral blood among patients with leukemias that were refractory to prior regimens. In addition, SNS-595 has been well tolerated, and patient accrual and dose escalation in this trial are ongoing."

Article continues below and (thank you)
 
Preliminary results from the trial show that SNS-595 reduces bone marrow blasts among relapsed, refractory acute myeloid leukemia (AML) patients treated with SNS-595 at 50 mg/m2 weekly for three doses. In particular, three of five evaluable patients treated at this dose level saw reductions in bone marrow blast cells of 95 percent or more after initial treatment with SNS-595; all of these patients had previously failed multiple treatments. SNS-595 was well tolerated, with only one dose-limiting toxicity (prolonged neutropenia) observed to date. All other non-dose-limiting toxicities have been easily manageable. In addition, SNS-595 has demonstrated highly predictable and reproducible pharmacokinetics, consistent with prior clinical trials.

The Phase 1 trial is designed to assess SNS-595's safety, tolerability and pharmacokinetics and to establish a recommended Phase 2 dose for further studies among patients with acute leukemia. To date, a total of 31 patients with advanced or refractory acute leukemias have been enrolled into one of two study arms in which patients receive escalating doses of SNS-595 weekly or twice weekly.

"We are pleased with these interim results from our Phase 1 trial of SNS- 595 among acute leukemia patients. We are seeing promising anticancer activity in our clinical trials and preclinical studies of SNS-595, and we are making excellent progress in defining a dose and schedule for further clinical development of this novel compound," said Daniel Adelman, M.D., Senior Vice President, Research and Development of Sunesis. "The goal of our program is to advance the 25-year-old standards of care in the treatment of AML. The distinct mechanism and resistance profile of SNS-595, combined with the promising preclinical and clinical data to date, support rapidly moving our drug into mono- and combination-therapy trials in AML in 2007."

In a poster session at the annual ASH meeting, Sunesis also presented preclinical data demonstrating that SNS-595 acts synergistically with cytarabine, or Ara C, a chemotherapy drug commonly used in the first-line treatment of acute myeloid leukemia. SNS-595 works through the DNA-protein kinase and p73 dependent pathways to induce apoptosis, or programmed cell death. Cytarabine also acts as a DNA-damaging agent, though it relies on a different pathway. Given the potentially complementary mechanisms, Sunesis conducted preclinical studies in a murine model of the two agents when administered alone or in combination to test for activity. Researchers found that low doses of SNS-595 and cytarabine in combination achieved greater reductions in cellularity than either SNS-595 or cytarabine administered alone. Notably, the two agents demonstrated synergy, reducing cellularity by 93 percent. In addition, circulating leukocyte levels were also reduced and complete bone marrow recovery was observed following treatment.

About Sunesis' Oncology Programs

Sunesis has built a portfolio of preclinical- and development-stage product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. Sunesis is currently conducting Phase 2 and Phase 1 clinical trials in lung cancer, and acute myeloid leukemia for its lead compound, SNS-595. A second compound, SNS-032, is in a Phase 1/2 clinical trial to examine the safety and preliminary anti-tumor activity among patients with lung cancer, breast cancer or melanoma. Sunesis is also conducting GLP toxicology studies of a third drug candidate, an Aurora kinase inhibitor known as SNS-314. In addition, in cooperation with Biogen Idec, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements. For further information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

Sunesis Pharmaceuticals, Inc.
http://www.sunesis.com
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page